Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA.

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

On average, patients who took 12 mg doses lost 11.5 lbs, or 5.8% of their body weight, while patients who were administered 36 mg doses lost 15.8 lbs, or 7.6% ... oral GLP-1 drug, Rybelsus ...

Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...

demand for Rybelsus, which is the oral version of semaglutide [7 mg and 14 mg], is declining not only because there is a more effective drug [Eli Lilly's Mounjaro] on the type 2 diabetes market ...

Novo Nordisk presented additional cardiovascular data this weekend for its blockbuster GLP-1 therapy semaglutide, touting the drug’s potential for ... SOUL trial found that while Novo’s Rybelsus—an ...

Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...